Dig Dis 2006;24:297–307
(DOI:10.1159/000092883)

Promotility Medications – Now and in the Future

Karamanolis G. · Tack J.
Center for Gastroenterological Research, KU Leuven, Leuven, Belgium
email Corresponding Author


 goto top of outline Key Words

  • Gastric emptying
  • Colonic transit
  • Gastroparesis
  • Functional dyspepsia
  • Constipation
  • Irritable bowel syndrome
  • Gastric accommodation
  • Antidopaminergic agents
  • Serotonergic agents
  • Motilin receptor agonists

 goto top of outline Abstract

Gastrointestinal promotility drugs stimulate smooth muscle contractions to enhance gastric emptying and small and large bowel transit. Currently available drug classes with prokinetic properties include antidopaminergic agents, serotonergic agents, and motilin-receptor agonists. Due to moderate prokinetic effects, poor symptomatic responses and the presence of adverse effects, there is a clear need for new classes of prokinetics. Several newer prokinetic drugs and drug classes are currently under evaluation. Selecting candidate agents and designing the appropriate therapeutic trials is hampered by the lack of insight in the pathophysiology of motility-related symptoms. As gastrointestinal motor disorders are chronic, relapsing, and remitting disorders, it seems desirable that studies with candidate prokinetic drugs establish a long-term efficacy and not only short-term effects on gastrointestinal functions.

Copyright © 2006 S. Karger AG, Basel


 goto top of outline References
  1. Orloff LA, Orloff MS, Bunnett NW, Walsh JH: Dopamine and norepinephrine in the alimentary tract changes after chemical sympathectomy and surgical vagotomy. Life Sci 1985;36:1625–1631.
  2. Demol P, Ruoff HJ, Weihrauch TR: Rational pharmacotherapy of gastrointestinal motility disorders. Eur J Pediatr 1989;148:489–495.
  3. Tonini M: Recent advances in the pharmacology of gastrointestinal prokinetics. Pharmacol Res 1996;33:217–226.
  4. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS: Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982;24:360–400.
  5. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS: Metoclopramide: a review of its pharmacological properties and clinical use. Drugs 1976;12:81–131.
  6. MacDonald TM: Metoclopramide, domperidone and dopamine in man: actions and interactions. Eur J Clin Pharmacol 1991;40:225–230.
  7. Horowitz M, Harding PE, Chattertin BE, Collins PJ, Shearman DJC: Acute and chronic effect of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985;30:1–9.
  8. Patterson D, Abell T, Rothstein R, Koch K, Barnett J: A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230–1234.
  9. Davis RH, Clench MH, Mathias JR: Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study. Dig Dis Sci 1988;33:1505–1511.
  10. Soykan I, Sarosiek I, McCallum RW: The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol 1997;92:976–980.
  11. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ: Efficacy of cisapride and domperidone in functional dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689–696.

    External Resources

  12. Finney JS, Kinnersley N, Hughes M, O’ Bryan-Tear CG, Lothian J: Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998;26:312–320.
  13. Sturm A, Holtmann G, Goebell H, Gerken G: Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999;60:422–427.
  14. Wiley J, Owyang C: Dopaminergic modulation of rectosigmoid motility: action of domperidone. J Pharmacol Exp Ther 1987;242:548–551.
  15. Milo R: Use of peripheral dopamine antagonist, domperidone, in the management of gastrointestinal symptoms in patients with irritable bowel syndrome. Curr Med Res Opin 1980;6:577–584.
  16. Tonini M, Cipollina L, Poluzzi E, Cremas F, Corazza GR, De Ponti F: Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004;19:379–390.
  17. Hasler WL: Pharmacotherapy for intestinal motor and sensory disorders. Gastroenterol Clin North Am 2003;32:707–732.
  18. Briejer MR, Akkermans LM, Schuurkes JA: Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995;47:631–651.
  19. American Gastroenterology Association: Technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004;127:1592–622.
  20. Longstreth GF, Malagelada JR, Kelly KA: Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis. Ann Intern Med 1977;86:195–196.
  21. Lata PF, Pigarelli DL: Chronic metoclopramide therapy for diabetic gastroparesis. Ann Pharmacother 2003;37:122–126.
  22. Ganzini L, Casey DE, Hoffman WF, McCall AL: The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993;153:1469–1475.
  23. Miller LG, Jankovic J: Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med 1989;149:2486–2492.
  24. Rossi F, Forgione A: Pharmatoxicological aspects of levosulpiride. Pharmacol Res 1995;31:81–94.
  25. Tonini M, De Giorgio R, Spelta V, et al: 5-HT4 receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract. Dis Liver Dis 2003;35:244–250.
  26. Corraza GR, Biagi F, Albano O, et al: Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial. Ital J Gastroenterol 1996;28:317–323.

    External Resources

  27. Arienti V, Corazza GR, Sorge M, et al: The effects of levosulpiride on gastric and gall-bladder emptying in functional dyspepsia. Aliment Pharmacol Ther 1994;8:631–638.
  28. Mansi C, Borro P, Giacomini M, et al: Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000;14:561–569.
  29. Mansi C, Savarino V, Vigneri S, et al: Gastrokinetic effects of levosulpiride in dyspeptic patients with diabetic gastroparesis. Am J Gastroenterol 1995;11:1989–1993.
  30. Mearin F, Rodrigo L, Perez-Mota A, et al: Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol 2004;2:301–308.
  31. Distrutti E, Fiorucci S, Hauer SK, et al: Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. Aliment Pharmacol Ther 2002;16:613–622.
  32. Iwanaga Y, Miyashita N, Morikawa K, et al: A novel water-soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity. Comparison with domperidone and neostigmine. Gastroenterology 1990;99:401–408.
  33. Kim YS, Kim TH, Chi CS, et al: Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol 2005;11:4210–4214.
  34. Amarapurkar DN, Rane P: Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. J Indian Med Assoc 2004;102:735–737.

    External Resources

  35. Sawant P, Das HS, Desai N, et al: Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. J Assoc Physicians India 2004;52:626–628.

    External Resources

  36. Holtmann G, Schmittker J, Boos G, et al: A randomized, double-blind, placebo-controlled dose-finding study of itopride for the treatment of patients with functional dyspepsia (abstract). Gastroenterology 2004;126:A100.

    External Resources

  37. Spiller R: Serotonergic modulating drugs for functional gastrointestinal disease. Br J Clin Pharmacol 2002;54:11–20.
  38. Cooke HJ, Harvey HV: The effects of cisapride on serotonin-evoked mucosal response in guinea pig ileum. Eur J Pharmacol 1984;98:147–148.
  39. De Ponti F, Malagelada JR: Drug treatment of functional gut disorders. Pharmacol Ther 1998;80:49–88.
  40. Frases RJ, Horowitz M, Maddox AF, Dent J: Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis – effects of cisapride. Gut 1994;35:172–178.
  41. Braden B, Enghofer M, Schaub M, et al: Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. Aliment Pharmacol Ther 2002;16:1341–1346.
  42. Tack J, Broeckaert D, Coulie B, Janssens J: The influence of cisapride on gastric tone and the perception of gastric distension. Aliment Pharmacol Ther 1998;12:761–766.
  43. Coremans G, Janssens J, Vantrappen G, et al: Cisapride stimulates propulsive motility patterns in human jejunum. Dig Dis Sci 1988;33:1512–1519.
  44. Madsen JL: Effects of cisapride on gastrointestinal transit in healthy humans. Dig Dis Sci 1990;35:1500–1504.
  45. Wiseman LR, Faulds D: Cisapride. An update review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994;47:116–152.
  46. Tonini M, De Ponti F, Di Nucci A, et al: Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999;13:1585–1591.
  47. Beattie DT, Smith JA, Marquess D, et al: The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2b receptor antagonist in vitro and in vivo. Br J Pharmacol 2004;143:549–560.
  48. Degan L, Matzinger D, Merz M, et al: Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745–1751.
  49. Prather CM, Camilleri M, Zinsmeister AR, et al: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463–468.
  50. Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, Gwee KA, Bak YT, Jones J, Wagner A: An Asia-Pacific, double-blind, placebo-controlled, randomised study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671–676.
  51. Muller-Lissner SA, Fumagali I, Bardhan KD, et al: Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655–1666.
  52. Novick J, Miner P, Krause R, et al: A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877–1888.
  53. American College of Gastroenterology Functional Gastrointestinal Disorders Task Force: Evidence-based position statement on the management of irritable bowel syndrome in North America. Am J Gastronterol 2002;97(suppl 2):S1–S5.
  54. Tack J, Muller-Lissner S, Bytzer P, et al: A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707–1713.
  55. Kamm MA, Muller-Lissner S, Talley NJ, et al: Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005;100:362–372.
  56. Johanson JF, Wald A, Tougas G, et al: Tegaserod is effective and well tolerated in chronic constipation: findings from a randomized, double-blind, placebo-controlled trial (abstract). Gastroenterology 2004;124:A64.
  57. Karhilas PJ, Quigley EM, Castell DO, Spechler TJ: The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:503–509.
  58. Di Stefano M, Vos R, Janssens J, Tack JF: Effect of tegaserod, a 5-HT4 receptor partial agonist, on interdigestive and postprandial gastrointestinal motility in healthy volunteers (abstract). Gastroenterology 2003;124:A163.

    External Resources

  59. Tougas G, Chen Y, Luo D, et al: Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms (abstract). Gastroenterology 2003;124:A54.

    External Resources

  60. Tack J, Vos R, Janssens J, et al: Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 2003;18:1031–1037.
  61. Tack J, Vos R, Bisschops R, et al: Influence of tegaserod, a partial 5-HT4 receptor agonist, on sensory and motor function of proximal stomach in functional dyspepsia. Gastroenterology 2005;128(4):A94–A95.
  62. Tack J, Delia T, Ligozio G, et al: A phase II trial with tegaserod in functional dyspepsia patients with normal gastric emptying (abstract). Gastroenterology 2002;120:A20.
  63. Fidelholtz J, Smith W, Rawls J, et al: Safety and tolerability of tegaserod in patients with irritable bowel disease and diarrhea symptoms. Am J Gastroenterol 2002;97:1176–1181.
  64. Dumuis A, Sebben M, Bockaert J: BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons. Eur J Pharmacol 1989;162:381–384.
  65. Briejer MR, Akkermans LMA, Schuurkes JAJ: Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev 1995;47:631–651.
  66. Potet F, Bouyssou T, Escande D, Baro I: Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K+ channel. J Pharmacol Exp Ther 2001;299:1007–1012.
  67. Camilleri M, McKinzie S, Fox J, Foxx-Orenstein A, Burton D, Thomforde G, et al: A randomized, controlled trial of renzapride on colonic motility in patients with constipa- tion-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2:895–904.
  68. Meyers NL, Palmer RMJ, George A: Efficacy and safety of renzapride in patients with constipation-predominant IBS: a phase IIb study in the UK Primary Healthcare Setting. Gastroenterology 2004;126:A640.
  69. Henderson JC, Palmer RMJ, Meyers NL, Spiller RC: A phase Iib clinical study of renzapride in mixed-symptom (alternating) irritable bowel syndrome. Gastroenterology 2004;126:A644.
  70. Tack J, Middleton SJ, Horne MC, Piessevaux H, Bloor JS, Meyers NL, Palmer RMJ: Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome (submitted).
  71. Meyers NL, Palmer RMJ, Wray HA, Bloor JR, Wilding IR: Effects of single oral doses of renzapride on gastrointestinal motility in fasted, healthy subjects (abstract). Gut 2002;51(suppl III):A137.
  72. Mackie AD, Ferrington C, Cowan S, et al: The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment Pharmacol Ther 1991;5:135–142.
  73. Kanaizumi T, Nakano N, Matsui Y, et al: Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol 1991;29:670–675.
  74. Ruth M, Finizia C, Cange L, Lundell L: The effect of mosapride on esophageal motor function and acid reflux in patients with gastro-esophageal reflux disease. Eur J Gastroenterol Hepatol 2003;15:1115–1121.

    External Resources

  75. Hallerback BI, Bommelaer G, Bredberg E, et al: Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002;16:959–967.
  76. Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG: Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999;13:1493–1497.
  77. Bouras EP, Camilleri M, Burton DD, Mc Kinzie S: Selective stimulation of colonic transit by the benzofuran 5-HT4 agonist, prucalopride, in healthy humans. Gut 1999;44:682–686.
  78. Bouras EP, Camilleri M, Burton DD, et al: Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354–360.
  79. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA: Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16:1347–1356.
  80. Coremans G, Kerstens R, De Pauw M, Stevens M: Prucalopride is effective in patients with severe chronic constipation in whom laxatives fails to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003;67:82–89.
  81. Tack J, Coulie B, Wilmer A, Andrioli A, Janssens J: Effect of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000;46:468–473.
  82. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998;115:1346–1352.
  83. Sarnelli G, Janssens J, Tack J: Effect of intranasal sumatriptan on gastric tone and sensitivity to distension. Dig Dis Sci 2000;46:1591–1595.
  84. Tack J, Piessevaux H, Coulie B, Fischler B, De Gucht V, Janssens J: A placebo-controlled trial of buspirone, a fundus relaxing drug in functional dyspepsia: effect on symptoms and gastric sensory and motor function (abstract). Gastroenterology 1999;116:A325.
  85. Boeckxstaens G, Tytgat G, Wajs E, Van Nueten L, De Ridder F, Tack J: The influence of the 5-HT1A agonist R-137696 on proximal stomach function in healthy volunteers (abstract). Gastroenterology 2004;126:A437.

    External Resources

  86. Tack J, Van Elzen B, Tytgat G, Wajs E, Van Nueten L, De Ridder F, Boeckxstaens G: A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia (abstract). Gastroenterology 2004;126:A70.

    External Resources

  87. Itoh Z: Motilin and clinical application. Peptides 1997;18:593–608.
  88. Depoortere I, Peeters TL, Vantrappen G: Motilin receptors of the rabbit colon. Peptides 1991;12:89–94.
  89. Peeters TL: Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993;105:186–199.
  90. Coulie B, Tack J, Peeters T, et al: Involvement of two different pathways in the motor effects of erythromycin on gastric antrum in humans. Gut 1998;43:395–400.
  91. Chaussade S, Michopoulos S, Sogni P, et al: Motilin agonist erythromycin increases human lower esophageal sphincter pressure by stimulation of cholinergic nerves. Dig Dis Sci 1994;39:381–384.
  92. Champion G, Richter JE, Singh S, et al: Effects of oral erythromycin on esophageal pH and pressure profile in patients with gastroesophageal reflux disease. Dig Dis Sci 1994;39:129–137.
  93. Janssens J, Peeters TL, Vantrappen G, et al: Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 1990;322:1028–1031.
  94. Richards RD, Davenport K, McCallum RW: The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993;88:203–207.
  95. Mozwecz H, Pavel D, Pitrak D, et al: Erythromycin stearate as prokinetic agent in postvagotomy gastroparesis. Dig Dis Sci 1990;7:902–905.

    External Resources

  96. Camilleri M: The current role of erythromycin in the clinical management of gastric emptying disorders. Am J Gastroentrol 1993;98:169–171.
  97. Magnanti K, Onyemere K, Jones MP: Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003;98:259–263.

    External Resources

  98. Tack J, Peeters T: What comes after macrolides and other motilin stimulants? Gut 2001;49:317–318.
  99. Arts J, Caenepeel P, Verbeke K, Tack J: Influence of erythromycin on gastric emptying and meal-related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005;54:455–460.
  100. Bruley des Varannes S, Parys V, Ropert A, et al: Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology 1995;109:32–39.
  101. Cuomo R, Tack J, Vandaele P, Coulie B, Peeters T, Depoortere I, Janssens J: Influence of motilin on gastric fundus tone and on meal-induced satiety in man. Am J Gastroenterol 2006 (in press).
  102. Kameling I, Van Haarst A, Burggraaf J, et al: Motilin effects on the proximal stomach in patients with functional dyspepsia and healthy volunteers. Am J Physiol 2003;284:G776–G781.
  103. Piessevaux H, Tack J, Wilmer A, et al: Perception of changes in wall tension of the proximal stomach in humans. Gut 2001;49:203–208.
  104. Minocha A, Katragadda R, Radal PS, Pres A: Erythromycin shortens orocaecal transit time in diabetic male subjects: a double-blind placebo-controlled study. Aliment Pharmacol Ther 1995;9:529–533.
  105. Jameson JS, Rogers J, Misiewics JJ, Raimundo AH: Oral or intravenous erythromycin has no effect on human distal colon motility. Aliment Pharmacol Ther 1992;6:589–595.
  106. Delvaux M, Louvel D, Fioramonti J, et al: Effect of various doses of erythromycin on colonic myoelectrical activity in IBS patients. Neurogastroenterol Motil 1994;6:205–212.

    External Resources

  107. Clark MJ, Wright T, Bertrand PP, et al: Erythromycin derivatives ABT 229 and GM 611 act on motilin receptors in the rabbit duodenum. Clin Exp Pharmacol Physiol 1999;26:242–245.
  108. Cowels VE, Nellans HN, Seifert TR, et al: Effect of novel motilide ABT-229 versus erythromycin and cisapride on gastric emptying in dogs. J Pharmacol Exp Ther 2000;293:1106–1111.
  109. Verhagen MA, Samson M, Maes B, et al: Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther 1997;11:1077–1086.
  110. Talley NJ, Verlinden M, Snape W, et al: Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000;14:1653–1661.
  111. Talley NJ, Verlinden M, Geenen DJ, et al: Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double-blind, placebo-controlled trial. Gut 2001;49:395–401.
  112. Van Herwaarden MA, Samson M, Van Nipsen CH, et al: The effect of motilin agonist ABT-229 on gastroesophageal reflux, oesophageal motility and lower sphincter characteristics in GERD patients. Aliment Pharmacol Ther 2000;14:453–462.

    External Resources

  113. Chen CL, Orr WC, Verlinden KH, et al: Efficacy of motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:749–757.
  114. Netzer P, Schmitt B, Inauen W: Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:1481–1490.
  115. Eeckhout C: Characterization of KC 11458 as a motilin agonist. Kali-Chemie Pharma GmbH, Report No. K.246.1005, 1995.
  116. Brett M, Steibrede H, Schubert CH, Hoofwijk TH: Singe, oral, rising-dose, placebo-controlled, double-blind study of KC 11458 to investigate safety, tolerability and pharmacokinetics in healthy male volunteers. Solvay Pharmaceuticals BV, Clin. Report No. S246.1.102.101, 199.
  117. Russo A, Stevens JE, Giles N, et al: Effect of the motilin agonist KC 11458 on gastric emptying in diabetic gastroparesis. Aliment Pharmacol Ther 2004;20:333–338.
  118. Peeters TL: GM-611 (Chugai Pharmaceutical). Curr Opin Investig Drugs 2001;2:555–557.
  119. Borovicka J, Kreiss C, Aral K, et al: Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans. Am J Physiol 1996;271:G448–G453.
  120. Wank SA: Cholecystokinin receptors. Am J Physiol 1995;296:G628–G646.
  121. Galligan JJ, Vanner S: Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol Motil 2005;17:1–11.

    External Resources

  122. Schwizer W, Borovicka J, Kunz P, et al: Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with CCK antagonist loxiglumide. Gut 1997;41:500–504.
  123. Feinle C, D’Amato M, Read NW: Cholecystokinin-A receptors modulate gastric sensory and motor responses to gastric distention and duodenal lipid. Gastroenterology 1996;110:1379–1385.
  124. Lal S, McLaughlin J, Barlow J, et al: Cholecystokinin pathways modulate sensations induced by gastric distension in humans. Am J Physiol 2004;287:G72–G79.
  125. Feinle C, Meier O, Otto B, et al: Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001;48:347–355.
  126. D’Amato M, Whorwell PJ, Thompson, et al: The efficacy and safety of the CCKA receptor antagonist dexloxiglumide in IBS (abstract). Gut 1999;45(suppl V):A258.
  127. Cremonini F, Camilleri M, McKinzie S, et al: Effect of CCK-1 antagonist dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol 2005;100:652–663.
  128. Wood JD, Galligan JJ: Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004;16(suppl 2):17–28.
  129. Greenwood-Van Meerveld B, Gardner CJ, Little PJ, et al: Preclinical studies of-opioids and-opioid antagonists on gastrointestinal function. Neurogastroenterol Motil 2004;16(suppl 2):46–53.
  130. Camilleri M: Alvimopan, a selective peripherally acting μ-opioid antagonist. Neurogastroenterol Motil 2005;17:157–165.
  131. Zimmerman DM, Gidda JS, Cantrell BE, et al: Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidin opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem 1994;37:2262–2265.
  132. Schmidt WK: Alvimopan (ADL 8-2698) is a novel peripheral-opioid antagonist. Am J Surg 2001;182:S27–S38.

    External Resources

  133. Taguchi A, Sharma N, Saleem RM, et al: Selective post-operative inhibition of gastrointestinal-opioid receptors. N Engl J Med 2001;345:935–941.
  134. Wolff BG, Michelassi F, Gerkin T, et al: Alvimopan, a novel peripherally acting μ-opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004;240:728–735.
  135. Barr WH, Nguyen P, Slattery M, et al: ADL 8-2698 reverses opiod-induced delay in colonic transit. Clin Pharmacol Ther 2000;67:91.

    External Resources

  136. Garnett W, Kelleher DL, Hickmott F, et al: Alvimopan shortens whole bowel transit time in adults with chronic constipation (abstract). Gastroenterology 2004;126:A643.

    External Resources

  137. Tack J, Masclee A, Heading R, et al: A dose-ranging, placebo-controlled, pilot trial of Z-338 in patients with functional dyspepsia (submitted).
  138. Mathias JR, Clench MH, Abell TL, et al: Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study. Dig Dis Sci 1998;43:1347–1355.
  139. Kojima M, Hosoda H, Date Y, et al: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656–660.
  140. Depoortere I, De Winter B, Thijs T, et al: Comparison of the gastroprokinetic effects of ghrelin, GHRP-6 and motilin in rats in vivo and in vitro. Eur J Pharmacol 2005;515:160–168.
  141. De Winter BY, De Man JG, Seerden TC, et al: Effect of ghrelin and growth hormone-releasing peptide 6 on septic ileus in mice. Neurogastroenterol Motil 2004;16:439–446.
  142. Tack J, Depoortere I, Bisschops R, et al: Influence of ghrelin on interdigestive gastrointestinal motility in man. Gut 2005. Oct 10 [Epub ahead of print].
  143. Tack J, Depoortere I, Bisschops R, et al: Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastropare sis. Aliment Pharmacol Ther 2005;22:847– 853.
  144. Azpiroz F, Malagelada JR: Vagally mediated gastric relaxation induced by intestinal nutrients in the dog. Am J Physiol 1986;251:G727–G735.
  145. Sanders KM, Ward SM: Nitric oxide as a mediator of nonadrenergic noncholinergic neurotransmission. Am J Physiol 1992;262:379–392.
  146. Kelly J, MacDonald A: Relaxant effect of α-adrenoceptor agonist in the rat isolated gastric fundus. J Pharm Pharmacol 1990;42:30–34.
  147. Gilja OH, Hausken T, Bang CJ, Berstad A: Effect of glyceryl trinitrate on gastric accommodation and symptoms in functional dyspepsia. Dig Dis Sci 1997;42:2124–2131.
  148. Sarnelli G, Sifrim D, Janssens J, Tack J: Influence of sildenafil on gastric sensorimotor function in man. Am J Physiol 2004;287:G988–G992.
  149. Thumshirn M, Camilleri M, Choi MG, Zinsmeister AR: Modulation of gastric sensory and motor functions by nitrergic and α2-adrenergic agents in humans. Gastroenterology 1999;116:573–585.

    External Resources

  150. Tack J, Caenepeel P, Corsetti M, Janssens J: Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention. Gastroenterology 2004;127:1058–1066.
  151. Asai T, McBeth C, Stewart JL, et al: Effect of clonidine on gastric emptying of liquids. Br J Anaesth 1997;78:28–33.
  152. Rosa-E-Silva L, Troncon LEA, Oliveira RB, et al: Treatment of diabetic gastroparesis with oral clonidine. Aliment Pharmacol Ther 1995;9:179–183.

 goto top of outline Author Contacts

Jan Tack, MD, PhD
Department of Internal Medicine, Division of Gastroenterology
University Hospital Gasthuisberg, Herestraat 49
BE–3000 Leuven (Belgium)
Tel. +32 16 345 751, Fax +32 16 345 939, E-Mail Jan.Tack@med.kuleuven.ac.be


 goto top of outline Article Information

Number of Print Pages : 11
Number of Figures : 0, Number of Tables : 0, Number of References : 152


 goto top of outline Publication Details

Digestive Diseases (Clinical Reviews)

Vol. 24, No. 3-4, Year 2006 (Cover Date: July 2006)

Journal Editor: Malfertheiner, P. (Magdeburg)
ISSN: 0257–2753 (print), 1421–9875 (Online)

For additional information: http://www.karger.com/DDI


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.